NEW YORK, Oct. 3 - Cynthia French , president of Diogenics, will join the senior management team of Pluvita as senior vice president of research and development after Pluvita acquired a majority stake in her company, as reported by GenomeWeb on Wednesday.
French is a molecular biologist with more than ten years of research and development experience in the biopharmaceutical industry. She has developed and commercialized a number of innovative products including both DNA and immunobased diagnostics and immunotherapeutics, and has directed R&D groups at both Fortune 500 and start-up health-care companies, including DuPont, Reprogen, BioRad, and Diagnostic Products Corporation.
NEW YORK, Oct. 2 - Third Wave Technologies has appointed John J. Puisis as its chief financial officer, the company said on Tuesday.
“Puisis brings two decades of strategic planning, business execution and financial experience to Third Wave, including work in an integral role in Dekalb Genetics’ initiative to improve its strategic and equity value, which culminated in its acquisition by Monsanto for $2.3 billion,” Third Wave said in a statement.
“John’s broad experience in strategic and financial planning and execution will be critical to Third Wave as we continue to aggressively implement our business model,” said Lance Fors, the company’s chairman and CEO.
Before joining Third Wave, Puisis was executive director of finance and strategy at Kraft Foods. He later held senior management positions at two leading executive recruitment firms specializing in recruiting for the biotechnology and pharmaceutical industries, most recently as the biotechnology sector head for Spencer Stuart.
NEW YORK, Oct. 2 – Biogen has appointed Burt Adelman executive vice
president, research and development, the company said on Tuesday.
According to Biogen, Adelman's new responsibilities will include all medical research, including clinical and preclinical activities; all research, including drug discovery; and worldwide regulatory affairs.
Adelman is most recently Biogen's vice president of Medical Research. He
joined Biogen in 1991 as director of medical research and has been vice president, development operations overseeing the preclinical development, medical operations and regulatory affairs, and vice president, regulatory affairs, Biogen said.
Since 1992, Adelman has held an appointment as a lecturer of medicine at Harvard Medical School, in Cambridge, Mass.
NEW YORK, Oct. 1 - MDS Proteomics , a proteomics-based drug discovery company, has hired two new directors to its informatics team, the company said on Monday.
Hugues Sicotte , a former staff scientist at the National Center for Biotechnology Information, and Peder Thusgaard Ruhoff , former director of the Maersk McKinney Moller Institute for Production Technology at the University of Southern Denmark, join the company's growing informatics division,
currently with more than 45 employees.
As director of the company's Toronto-based bioinformatics team, Sicotte will be responsible for the overall development of MDS’ bioinformatics and supercomputing software platform. Ruhoff, meanwhile, director of informatics research, will lead the company's Odense, Denmark-based proteomics and laboratory automation software team in its efforts to enhance the company's mass spectrometry software.